Top Markets
#1 Audiera Audiera +42.05%
#2 Tutorial Tutorial +36.83%
#3 Fabric Protocol Fabric Protocol +31.97%
#4 Binance-Peg Bitcoin Cash Binance-Peg Bitcoin Cash +29.92%
#5 Bitcoin Cash Bitcoin Cash +29.09%
#6 Prom Prom +27.15%
#7 GALA GALA +27.03%
#8 Ethena Staked ENA Ethena Staked ENA +26.37%
#9 Arowana Arowana +26.33%
#10 Useless Coin Useless Coin +24.77%
Coin of the day
Audiera Audiera
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Elicio Therapeutics, Inc. Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc.

ELTX
Rang in Aktien #24601
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to... Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
Aktienkurs
$3.09
Marktkapitalisierung
$58.82M
Veränderung (1 Tag)
0.33%
Veränderung (1 Jahr)
-73.01%
Land
US
Handel Elicio Therapeutics, Inc. (ELTX)

Kategorie

Healthcare
P/B-Verhältnis für Elicio Therapeutics, Inc. (ELTX)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Elicio Therapeutics, Inc. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für Elicio Therapeutics, Inc. von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH